DAVITA INC.: management transactions · United States · SEC (Form 4)

About DAVITA INC.

DaVita Inc. (ticker: DVA) is a leading U.S. healthcare services company listed on the NYSE/NASDAQ market in the United States, with a business model focused on chronic kidney disease care and outpatient dialysis. Founded in 1979, DaVita has spent decades building a scaled position in renal care, combining the operation of dialysis centers with clinical coordination and related patient support services. The company is headquartered in Denver, Colorado, United States. DaVita’s core economics are driven by a large outpatient dialysis network that serves patients requiring recurring, long-duration treatments. Its main offering is in-center dialysis, supported by clinical management, patient education, and care coordination capabilities that help manage the complex needs of end-stage kidney disease patients. The company also operates internationally, giving it a broader geographic footprint, although the United States remains the dominant market for revenue, patients, and operating scale. From a competitive standpoint, DaVita is one of the major specialized providers in the U.S. dialysis market. Its scale, dense center network, operating know-how, and long-standing relationships with patients, physicians, and payers create meaningful entry barriers. At the same time, the sector is highly regulated and exposed to reimbursement trends, compliance requirements, labor pressures, and broader healthcare cost dynamics. For investors, that means DaVita often screens as a defensive healthcare services name, but one where execution quality and policy sensitivity matter greatly. In terms of products and services, DaVita is not a product manufacturer in the traditional sense. Its offering is primarily service-based: outpatient dialysis, renal care management, and associated clinical services. For French-speaking investors, this makes DaVita best understood as a healthcare services platform rather than a pharmaceutical or biotech company. The investment case is therefore more tied to patient volumes, center utilization, reimbursement stability, and operating efficiency than to drug pipelines or patent cycles. Recent company disclosures indicate continued operational scale. As of March 31, 2026, DaVita reported serving approximately 296,300 patients across 3,262 outpatient dialysis centers, including 2,666 centers in the United States and 596 centers in 14 other countries. In early May 2026, the company released first-quarter 2026 results and also disclosed ongoing share repurchases, underscoring capital allocation discipline. For market participants, the key themes remain patient growth, margin management, cash generation, and regulatory or reimbursement developments. As a publicly traded healthcare provider on the NYSE/NASDAQ in the United States, DaVita remains a reference name in specialized renal services.